| Dr Natasha N Hardeman, MD | |
|
2506 Lakeland Dr Ste 600, Flowood, MS 39232-7640 | |
| (601) 939-1600 | |
| (601) 939-1606 |
| Full Name | Dr Natasha N Hardeman |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 2506 Lakeland Dr Ste 600, Flowood, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104869148 | NPI | - | NPPES |
| 07926573 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VG0400X | Obstetrics & Gynecology - Gynecology | 18064 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Merit Health Women's Hospital | Flowood, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lakeland Premier Women's Clinic Pllc | 5193069060 | 3 |
| Southern Women's Health, Pllc | 2567497985 | 38 |
News Archive
U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."
For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN), promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney (graft loss), according to a report in the November Clinical Journal of the American Society of Nephrology (CJASN).
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Entity Name | Southern Women's Health, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174744379 PECOS PAC ID: 2567497985 Enrollment ID: O20051004000733 |
News Archive
U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."
For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN), promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney (graft loss), according to a report in the November Clinical Journal of the American Society of Nephrology (CJASN).
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Entity Name | East Lakeland Ob Gyn Associates, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235220112 PECOS PAC ID: 5496836504 Enrollment ID: O20080610000691 |
News Archive
U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."
For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN), promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney (graft loss), according to a report in the November Clinical Journal of the American Society of Nephrology (CJASN).
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Entity Name | Lakeland Premier Women's Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457836637 PECOS PAC ID: 5193069060 Enrollment ID: O20181204000247 |
News Archive
U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."
For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN), promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney (graft loss), according to a report in the November Clinical Journal of the American Society of Nephrology (CJASN).
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Natasha N Hardeman, MD 2506 Lakeland Dr Ste 600, Flowood, MS 39232-7640 Ph: (601) 939-1600 | Dr Natasha N Hardeman, MD 2506 Lakeland Dr Ste 600, Flowood, MS 39232-7640 Ph: (601) 939-1600 |
News Archive
U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."
For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN), promptly cutting back on anti-rejection drugs reduces the risk of losing the kidney (graft loss), according to a report in the November Clinical Journal of the American Society of Nephrology (CJASN).
iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
Dr. Charles Shannon Carroll, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 291 E Layfair Dr, Flowood, MS 39232 Phone: 601-936-9190 Fax: 601-932-6714 | |
Dr. Joel G Payne Jr., MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 291 E Layfair Dr, Flowood, MS 39232 Phone: 601-936-9190 Fax: 601-932-6714 | |
Mrs. Kay Elizabeth Midler, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1050 River Oaks Drive, Suite 200, Flowood, MS 39232 Phone: 601-200-8201 Fax: 601-987-0019 | |
Dr. John W Cook, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 291 E Layfair Dr, Flowood, MS 39232 Phone: 601-936-9190 Fax: 601-932-6714 | |
Dr. Shimeka Lanette Banks, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1307-b Airport Road North, Flowood, MS 39232 Phone: 601-825-7280 | |
Dr. Lindsey Miller Turner, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1020 River Oaks Dr Ste 320, Flowood, MS 39232 Phone: 601-936-1400 Fax: 601-936-1416 |